From Basic Science to Clinical Application of Polygenic Risk Scores A Primer

被引:190
作者
Wray, Naomi R. [1 ,2 ]
Lin, Tian [1 ]
Austin, Jehannine [3 ,4 ,5 ]
McGrath, John J. [2 ,6 ,7 ]
Hickie, Ian B. [8 ,9 ]
Murray, Graham K. [1 ,9 ,10 ]
Visscher, Peter M. [1 ]
机构
[1] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4067, Australia
[2] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia
[3] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada
[4] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada
[5] BC Mental Hlth & Subst Use Serv Res Inst, Vancouver, BC, Canada
[6] Pk Ctr Mental Hlth, Queensland Ctr Mental Hlth Res, Wacol, Qld, Australia
[7] Aarhus Univ, Natl Ctr Register Based Res, Aarhus, Denmark
[8] Univ Sydney, Fac Med & Hlth, Brain & Mind Ctr, Sydney, NSW, Australia
[9] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge, England
[10] Univ Cambridge, Dept Psychiat, Cambridge, England
基金
英国医学研究理事会; 新加坡国家研究基金会; 澳大利亚研究理事会;
关键词
CORONARY-ARTERY-DISEASE; PREDICTIVE ACCURACY; GENETIC RISK; HERITABILITY; PSYCHIATRY;
D O I
10.1001/jamapsychiatry.2020.3049
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Importance Polygenic risk scores (PRS) are predictors of the genetic susceptibilities of individuals to diseases. All individuals have DNA risk variants for all common diseases, but genetic susceptibility differences between people reflect the cumulative burden of these. Polygenic risk scores for an individual are calculated as weighted counts of thousands of risk variants that they carry, where the risk variants and their weights have been identified in genome-wide association studies. Here, we review the underlying basic science of PRS, providing a foundation for understanding the potential clinical utility and limitations of PRS. Observations Polygenic risk scores can be calculated for a wide range of diseases from a saliva or blood sample using genotyping technologies that are inexpensive. While genotyping only needs to be done once for each individual in their lifetime, the PRS can be recalculated as identification of risk variants improves. On their own, PRS will never be able to establish or definitively predict future diagnoses of common complex conditions because genetic factors only contribute part of the risk, and PRS will only ever capture part of the genetic contributions. Nonetheless, just as clinical medicine uses a multitude of other predictive measures, PRS either on their own or as part of multivariable predictive algorithms could play a role. Conclusions and Relevance Utility of PRS in clinical medicine and ethical issues related to their use should be evaluated in the context of realistic expectations of what PRS can and cannot deliver. For different diseases, PRS could have utility in community settings (stratification to better triage people into established screening programs) or could contribute to clinical decision-making for those presenting with symptoms but where formal diagnosis is unclear. In principle, PRS could contribute to treatment choices, but more data are needed to allow development of PRS in this context. This review provides a foundation for understanding the basic science as well as the potential clinical utility and limitations of polygenic risk scores.
引用
收藏
页码:101 / 109
页数:9
相关论文
共 49 条
  • [21] Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?
    Kapur, S.
    Phillips, A. G.
    Insel, T. R.
    [J]. MOLECULAR PSYCHIATRY, 2012, 17 (12) : 1174 - 1179
  • [22] Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
    Khera, Amit V.
    Chaffin, Mark
    Aragam, Krishna G.
    Haas, Mary E.
    Roselli, Carolina
    Choi, Seung Hoan
    Natarajan, Pradeep
    Lander, Eric S.
    Lubitz, Steven A.
    Ellinor, Patrick T.
    Kathiresan, Sekar
    [J]. NATURE GENETICS, 2018, 50 (09) : 1219 - +
  • [23] Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers
    Kuchenbaecker, Karoline B.
    McGuffog, Lesley
    Barrowdale, Daniel
    Lee, Andrew
    Soucy, Penny
    Dennis, Joe
    Domchek, Susan M.
    Robson, Mark
    Spurdle, Amanda B.
    Ramus, Susan J.
    Mavaddat, Nasim
    Terry, Mary Beth
    Neuhausen, Susan L.
    Schmutzler, Rita Katharina
    Simard, Jacques
    Pharoah, Paul D. P.
    Offit, Kenneth
    Couch, Fergus J.
    Chenevix-Trench, Georgia
    Easton, Douglas F.
    Antoniou, Antonis C.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (07):
  • [24] Towards clinical utility of polygenic risk scores
    Lambert, Samuel A.
    Abraham, Gad
    Inouye, Michael
    [J]. HUMAN MOLECULAR GENETICS, 2019, 28 (R2) : R133 - R142
  • [25] Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores
    Lecarpentier, Julie
    Silvestri, Valentina
    Kuchenbaecker, Karoline B.
    Barrowdale, Daniel
    Dennis, Joe
    McGuffog, Lesley
    Soucy, Penny
    Leslie, Goska
    Rizzolo, Piera
    Navazio, Anna Sara
    Valentini, Virginia
    Zelli, Veronica
    Lee, Andrew
    Al Olama, Ali Amin
    Tyrer, Jonathan P.
    Southey, Melissa
    John, Esther M.
    Conner, Thomas A.
    Goldgar, David E.
    Buys, Saundra S.
    Janavicius, Ramunas
    Steele, Linda
    Ding, Yuan Chun
    Neuhausen, Susan L.
    Hansen, Thomas V. O.
    Osorio, Ana
    Weitzel, Jeffrey N.
    Toss, Angela
    Medici, Veronica
    Cortesi, Laura
    Zanna, Ines
    Palli, Domenico
    Radice, Paolo
    Manoukian, Siranoush
    Peissel, Bernard
    Azzollini, Jacopo
    Viel, Alessandra
    Cini, Giulia
    Damante, Giuseppe
    Tommasi, Stefania
    Peterlongo, Paolo
    Fostira, Florentia
    Hamann, Ute
    Evans, D. Gareth
    Henderson, Alex
    Brewer, Carole
    Eccles, Diana
    Cook, Jackie
    Ong, Kai-ren
    Walker, Lisa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (20) : 2240 - +
  • [26] BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors
    Lee, Andrew
    Mavaddat, Nasim
    Wilcox, Amber N.
    Cunningham, Alex P.
    Carver, Tim
    Hartley, Simon
    de Villiers, Chantal Babb
    Izquierdo, Angel
    Simard, Jacques
    Schmidt, Marjanka K.
    Walter, Fiona M.
    Chatterjee, Nilanjan
    Garcia-Closas, Montserrat
    Tischkowitz, Marc
    Pharoah, Paul
    Easton, Douglas F.
    Antoniou, Antonis C.
    [J]. GENETICS IN MEDICINE, 2019, 21 (08) : 1708 - 1718
  • [27] Polygenic risk scores: from research tools to clinical instruments
    Lewis, Cathryn M.
    Vassos, Evangelos
    [J]. GENOME MEDICINE, 2020, 12 (01)
  • [28] Framingham risk score and prediction of lifetime risk for coronary heart disease
    Lloyd-Jones, DM
    Wilson, PWF
    Larson, MG
    Beiser, A
    Leip, EP
    D'Agostino, RB
    Levy, D
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (01) : 20 - 24
  • [29] Evaluation of polygenic risk models using multiple performance measures: a critical assessment of discordant results
    Martens, Forike K.
    Tonk, Elisa C. M.
    Janssens, A. Cecile J. W.
    [J]. GENETICS IN MEDICINE, 2019, 21 (02) : 391 - 397
  • [30] Clinical use of current polygenic risk scores may exacerbate health disparities
    Martin, Alicia R.
    Kanai, Masahiro
    Kamatani, Yoichiro
    Okada, Yukinori
    Neale, Benjamin M.
    Daly, Mark J.
    [J]. NATURE GENETICS, 2019, 51 (04) : 584 - 591